Endometriosis Blood Test Could Replace Invasive Laparoscopic Diagnosis

Endometriosis affects an estimated 1 in 10 women globally, yet diagnosis can take 7 to 10 years on average due to the invasive nature of laparoscopy and lack of accurate, non-invasive tests. This diagnostic delay can lead to chronic pain, infertility, and irreversible organ damage. Now, a novel test utilizes mitochondrial DNA (mtDNA) biomarkers to detect molecular signatures associated with endometriosis, enabling earlier detection through a simple blood draw.

Pearsanta’s (Richmond, VA, USA) Mitomic Endometriosis Test (MET) is a blood-based diagnostic that leverages its proprietary Mitomic Technology to aid in the early detection of endometriosis. Pearsanta’s proprietary Mitomic Technology Platform leverages the unique properties of mtDNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid biopsy tests. MET offers a non-invasive alternative to laparoscopic diagnosis, which is currently considered the gold standard for confirming endometriosis.

Image: The test utilizes mtDNA biomarkers to detect molecular signatures associated with endometriosis (Photo courtesy of Shutterstock)

Pearsanta has begun enrollment in a prospective clinical study to evaluate the diagnostic performance and generate real-world data for MET. The study aims to evaluate the sensitivity and specificity of MET in detecting endometriosis compared to laparoscopic diagnosis. The study will enroll up to 1,000 participants who are referred for diagnostic laparoscopy. Each participant will complete a symptom questionnaire and provide a pre-operative blood sample.

The study will assess the test’s performance across various disease subtypes to understand its utility in different clinical presentations. The researchers will also explore the correlations between MET’s results, symptom profiles, and demographic variables to support personalized diagnostic insights.

“This represents another major milestone in our path to validate a diagnostic tool that addresses a critical gap in women’s health,” said Chris Mitton, President of Pearsanta. “This study will generate real-world data on the clinical performance of MET in a pre-surgical population, helping us evaluate its accuracy across symptom profiles and disease subtypes. By targeting mtDNA deletions, MET is designed as a non-invasive alternative to current surgical diagnostic approaches, bringing us closer to delivering earlier, more accessible detection for patients affected by endometriosis.”

Related Links:
Pearsanta